Sareum Holdings plc reported that the licensing partner for its FLT3+Aurora kinase programme has decided not to exercise its option to continue the development of the programme. Sareum received formal confirmation of the Licensee's decision. Worldwide rights to the FLT3 programme, as well as data relating to progress made by the Licensee, will therefore revert to Sareum.